Tag archive for ‘Advanced solid tumors’
Gan & Lee gets EMA orphan drug status for GLR2007 in glioma
By businessnewstoday On Tuesday, April 6th, 2021
0 Comments

Gan & Lee gets EMA orphan drug status for GLR2007 in glioma

Gan & Lee Pharmaceuticals has been granted orphan drug designation for GLR2007 from the European Medicine Agency (EMA) for the treatment of glioma, a type of tumor found in the brain and spinal cord. The Chinese More...

By pharmanewsdaily On Saturday, October 13th, 2018
0 Comments

BMS, Compugen to trial COM701 Opdivo combo in advanced solid tumors

US biopharma company Bristol-Myers Squibb (BMS) has entered into a clinical collaboration with Compugen to evaluate the combination of its cancer drug Opdivo (nivolumab) with the Israeli genomics-based drug and More...

By pharmanewsdaily On Tuesday, September 11th, 2018
0 Comments

Alkermes to evaluate ALKS 4230, pembrolizumab combo for solid tumors

Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety and anti-tumor activity in combination with Merck’s PD-1 inhibitor More...

By pharmanewsdaily On Saturday, September 8th, 2018
0 Comments

Compugen kickstarts phase 1 trial of cancer immunotherapy COM701

Israeli pharma company Compugen has dosed the first patient in the phase 1 clinical trial which is evaluating the company’s cancer immunotherapy antibody COM701 in patients with advanced solid tumors. COM701 has More...

By pharmanewsdaily On Sunday, July 15th, 2018
0 Comments

Xencor launches phase 1 trial of XmAb20717 in advanced solid tumors

Xencor has launched a phase 1 clinical trial of its bispecific antibody XmAb20717, which is being developed for the treatment of multiple advanced solid tumors. The California-based biopharma company has dosed the More...